We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Read MoreHide Full Article
Castle Biosciences, Inc. (CSTL - Free Report) is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $85.7 million, while the same for earnings is pinned at 11 cents per share.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
In the past year, shares of Castle Biosciences have increased 5.1% against the industry’s decline of 8.7%.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up prior to the announcement.
Factors Likely to Influence CSTL's Q4 Results
Castle Biosciences offers innovative test solutions to help clinicians diagnose and treat dermatologic cancers, Barrett’s esophagus (“BE”), uveal melanoma (“UM”) and mental health conditions.
The company’s commercial portfolio consists of tests for skin cancers, BE, UM and mental health conditions.
Revenues in the to-be-reported quarter are likely to have been driven by higher sales from the above-mentioned tests.
Last month, Castle Biosciences reported preliminary results for the fourth quarter of 2024. The company delivered 24,071 total test reports in the fourth quarter of 2024.
Owing to the strong business performance, the company raised its revenue guidance for 2024 in the last reported quarter. In January 2025, management announced that it expects to meet or exceed the top end of its full-year 2024 revenue guidance of $320-330 million.
Activities related to the research, development and commercialization of new tests might have escalated operating expenses in the to-be-reported quarter.
Earnings Surprise History
Castle Biosciences has an excellent history of earnings surprises. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 172.72%. In the last reported quarter, CSTL posted an earnings surprise of 233.33%.
Our proven model does not conclusively predict an earnings beat for CSTL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: Castle Biosciences’ Earnings ESP is 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 11 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Here are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +2.34% and a Zacks Rank #1 at present.
Shares of PCRX have declined 15.4% in the past year. PCRX beat earnings estimates in two of the trailing four quarters, met once and missed the same on the remaining occasion, delivering an average surprise of 7.13%. Pacira is scheduled to report fourth-quarter results on Feb. 27.
Mirum Pharmaceuticals, Inc. (MIRM - Free Report) has an Earnings ESP of +24.63% and a Zacks Rank #2 at present.
Shares of MIRM have surged 80.5% in the past year. MIRM beat on earnings in one of the trailing four quarters while missing the same in the remaining three occasions, delivering an average negative surprise of 26.03%. Mirum is scheduled to report fourth-quarter results on Feb. 26.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know
Castle Biosciences, Inc. (CSTL - Free Report) is scheduled to report fourth-quarter and full-year 2024 results on Feb. 27, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $85.7 million, while the same for earnings is pinned at 11 cents per share.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
In the past year, shares of Castle Biosciences have increased 5.1% against the industry’s decline of 8.7%.
Image Source: Zacks Investment Research
Let’s see how things might have shaped up prior to the announcement.
Factors Likely to Influence CSTL's Q4 Results
Castle Biosciences offers innovative test solutions to help clinicians diagnose and treat dermatologic cancers, Barrett’s esophagus (“BE”), uveal melanoma (“UM”) and mental health conditions.
The company’s commercial portfolio consists of tests for skin cancers, BE, UM and mental health conditions.
Revenues in the to-be-reported quarter are likely to have been driven by higher sales from the above-mentioned tests.
Last month, Castle Biosciences reported preliminary results for the fourth quarter of 2024. The company delivered 24,071 total test reports in the fourth quarter of 2024.
Owing to the strong business performance, the company raised its revenue guidance for 2024 in the last reported quarter. In January 2025, management announced that it expects to meet or exceed the top end of its full-year 2024 revenue guidance of $320-330 million.
Activities related to the research, development and commercialization of new tests might have escalated operating expenses in the to-be-reported quarter.
Earnings Surprise History
Castle Biosciences has an excellent history of earnings surprises. The company beat on earnings in each of the trailing four quarters, delivering an average surprise of 172.72%. In the last reported quarter, CSTL posted an earnings surprise of 233.33%.
Castle Biosciences, Inc. Price and EPS Surprise
Castle Biosciences, Inc. price-eps-surprise | Castle Biosciences, Inc. Quote
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for CSTL this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below.
Earnings ESP: Castle Biosciences’ Earnings ESP is 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 11 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Zacks Rank: CSTL has a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are some stocks worth considering from the healthcare space, as our model shows that these have the right combination of elements to beat on earnings this reporting cycle.
Pacira BioSciences, Inc. (PCRX - Free Report) has an Earnings ESP of +2.34% and a Zacks Rank #1 at present.
Shares of PCRX have declined 15.4% in the past year. PCRX beat earnings estimates in two of the trailing four quarters, met once and missed the same on the remaining occasion, delivering an average surprise of 7.13%. Pacira is scheduled to report fourth-quarter results on Feb. 27.
Mirum Pharmaceuticals, Inc. (MIRM - Free Report) has an Earnings ESP of +24.63% and a Zacks Rank #2 at present.
Shares of MIRM have surged 80.5% in the past year. MIRM beat on earnings in one of the trailing four quarters while missing the same in the remaining three occasions, delivering an average negative surprise of 26.03%. Mirum is scheduled to report fourth-quarter results on Feb. 26.